Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast for Severe Recurrent Aphthous Stomatitis
NCT03690544Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Oct 2018
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of apremilast in recurrent aphthous stomatitis (RAS), sponsored by Mayo Clinic. Primary endpoints: Duration of RAS Lesions at 24 weeks, Change in Number of RAS Lesions at 24 weeks and 1 more. Started Oct 2018; status: completed.
02
Drugs
apremilast
03
Conditions
recurrent aphthous stomatitis (RAS)
Beyond the preview
Go deeper on NCT03690544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690544.